Compass Wealth Management LLC Takes $541,000 Position in Grifols, S.A. (NASDAQ:GRFS)

Compass Wealth Management LLC acquired a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 76,116 shares of the biotechnology company's stock, valued at approximately $541,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GRFS. Norges Bank bought a new stake in shares of Grifols in the 4th quarter valued at about $14,434,000. Sequoia Financial Advisors LLC grew its holdings in shares of Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after acquiring an additional 3,399 shares during the period. LPL Financial LLC grew its holdings in shares of Grifols by 25.0% during the 4th quarter. LPL Financial LLC now owns 75,398 shares of the biotechnology company's stock worth $561,000 after acquiring an additional 15,067 shares during the period. First Trust Advisors LP purchased a new position in shares of Grifols during the 4th quarter worth approximately $75,000. Finally, GAMMA Investing LLC grew its holdings in shares of Grifols by 426.1% during the 1st quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock worth $1,850,000 after acquiring an additional 21,128 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have commented on GRFS shares. JPMorgan Chase & Co. increased their target price on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday.

Grifols Price Performance

Shares of NASDAQ GRFS traded up $0.39 during mid-day trading on Wednesday, reaching $9.39. The company's stock had a trading volume of 3,233,169 shares, compared to its average volume of 1,098,592. The stock has a fifty day moving average of $8.32 and a two-hundred day moving average of $7.72. Grifols, S.A. has a 52 week low of $6.19 and a 52 week high of $9.96. The firm has a market capitalization of $6.46 billion, a PE ratio of 8.03, a P/E/G ratio of 0.32 and a beta of 0.55. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.60 and a quick ratio of 0.97.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.